Purple Biotech Updates Company Presentation
Ticker: PPBT · Form: 6-K · Filed: Mar 6, 2024 · CIK: 1614744
Sentiment: neutral
Topics: company-update, investor-relations
TL;DR
Purple Biotech dropped a new investor deck, check it out.
AI Summary
Purple Biotech Ltd. announced on March 6, 2024, that it has made an updated Company Presentation available on its website. This presentation is attached as Exhibit 99.1 to the filing.
Why It Matters
Investors can access the latest information about Purple Biotech's strategy and progress through the updated presentation.
Risk Assessment
Risk Level: low — This filing is an informational update and does not contain material financial or operational changes.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer and subject of the report
- Exhibit 99.1 (document) — Attached updated Company Presentation
FAQ
What is the purpose of this 6-K filing?
The purpose of this 6-K filing is to announce that Purple Biotech Ltd. has made an updated Company Presentation available on its website.
When was this announcement made?
The announcement was made on March 6, 2024.
Where can the updated Company Presentation be found?
The updated Company Presentation is available on Purple Biotech Ltd.'s website and is attached as Exhibit 99.1 to this filing.
What is the Commission File Number for Purple Biotech Ltd.?
The Commission File Number for Purple Biotech Ltd. is 001-37643.
Does Purple Biotech Ltd. file annual reports under Form 20-F or 40-F?
Purple Biotech Ltd. indicates that it files annual reports under Form 20-F.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 19.9 · Accepted 2024-03-06 16:06:16
Filing Documents
- ea0201303-6k_purplebio.htm (6-K) — 13KB
- ea0201303ex99-1_purplebio.htm (EX-99.1) — 55KB
- ex99-1_001.jpg (GRAPHIC) — 129KB
- ex99-1_002.jpg (GRAPHIC) — 1506KB
- ex99-1_003.jpg (GRAPHIC) — 96KB
- ex99-1_004.jpg (GRAPHIC) — 211KB
- ex99-1_005.jpg (GRAPHIC) — 158KB
- ex99-1_006.jpg (GRAPHIC) — 189KB
- ex99-1_007.jpg (GRAPHIC) — 691KB
- ex99-1_008.jpg (GRAPHIC) — 271KB
- ex99-1_009.jpg (GRAPHIC) — 687KB
- ex99-1_010.jpg (GRAPHIC) — 239KB
- ex99-1_011.jpg (GRAPHIC) — 236KB
- ex99-1_012.jpg (GRAPHIC) — 177KB
- ex99-1_013.jpg (GRAPHIC) — 117KB
- ex99-1_014.jpg (GRAPHIC) — 126KB
- ex99-1_015.jpg (GRAPHIC) — 738KB
- ex99-1_016.jpg (GRAPHIC) — 462KB
- ex99-1_017.jpg (GRAPHIC) — 124KB
- ex99-1_018.jpg (GRAPHIC) — 237KB
- ex99-1_019.jpg (GRAPHIC) — 601KB
- ex99-1_020.jpg (GRAPHIC) — 857KB
- ex99-1_021.jpg (GRAPHIC) — 724KB
- ex99-1_022.jpg (GRAPHIC) — 112KB
- ex99-1_023.jpg (GRAPHIC) — 234KB
- ex99-1_024.jpg (GRAPHIC) — 180KB
- ex99-1_025.jpg (GRAPHIC) — 208KB
- ex99-1_026.jpg (GRAPHIC) — 236KB
- ex99-1_027.jpg (GRAPHIC) — 97KB
- ex99-1_028.jpg (GRAPHIC) — 110KB
- ex99-1_029.jpg (GRAPHIC) — 81KB
- ex99-1_030.jpg (GRAPHIC) — 599KB
- ex99-1_031.jpg (GRAPHIC) — 553KB
- ex99-1_032.jpg (GRAPHIC) — 220KB
- ex99-1_033.jpg (GRAPHIC) — 259KB
- ex99-1_034.jpg (GRAPHIC) — 163KB
- ex99-1_035.jpg (GRAPHIC) — 43KB
- ex99-1_036.jpg (GRAPHIC) — 162KB
- ex99-1_037.jpg (GRAPHIC) — 135KB
- ex99-1_038.jpg (GRAPHIC) — 693KB
- ex99-1_039.jpg (GRAPHIC) — 220KB
- ex99-1_040.jpg (GRAPHIC) — 397KB
- ex99-1_041.jpg (GRAPHIC) — 250KB
- ex99-1_042.jpg (GRAPHIC) — 499KB
- ex99-1_043.jpg (GRAPHIC) — 177KB
- 0001213900-24-020425.txt ( ) — 19637KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. March 6, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2